Amneal Pharmaceuticals, Inc. (AMRX)

Current Report Filed: 2026-04-22

Amneal is acquiring Kashiv BioSciences for $375M in cash plus 28.9M shares of stock, with potential contingent payments up to $350M based on regulatory milestones and 25% royalties on profits over 12 years, representing a significant expansion of the company's product pipeline.
Related party transaction involves sellers who are affiliates of the Amneal Group; an independent Conflicts Committee of five directors negotiated and unanimously approved the deal, mitigating governance concerns and ensuring fair treatment of disinterested stockholders.
Acquisition requires stockholder approval (majority vote on stock issuance and deal terms) and regulatory clearance including HSR antitrust review, with expected closing in H2 2026 and an outside date of November 17, 2026 (extendable to January 12, 2027 if regulatory approvals pending).
The deal is not subject to financing conditions, indicating Amneal has sufficient liquidity or committed capital, though the substantial dilution from 28.9M new shares and contingent payment structure create financial commitments worth exploring in earnings calls.

Insider Trading Filed: 2026-03-05

Nikita Shah, the Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX), has exercised a significant number of restricted stock units (RSUs) and performance-based restricted stock units (PRSUs) on March 3, 2026, indicating their confidence in the company's long-term growth.
The filing shows that Shah has sold a portion of the shares acquired through the vesting of RSUs and PRSUs, likely to cover tax withholding obligations, while retaining a substantial number of shares, suggesting their continued alignment with shareholders.
The vesting of the PRSUs was triggered by the company's stock price achieving certain performance targets, which could signal strong financial performance and positive market sentiment towards Amneal Pharmaceuticals.

Insider Trading Filed: 2026-03-05

The reporting person, Andrew S. Boyer, who is the Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX), has engaged in a series of transactions involving the vesting and settlement of restricted stock units and performance-based restricted stock units.
The transactions indicate that the reporting person is holding a significant amount of Amneal's Class A Common Stock, with a total beneficial ownership of over 400,000 shares following the reported transactions.
The vesting and settlement of the performance-based restricted stock units suggest that the company has met certain performance targets, which could be a positive indicator for the company's financial and operational performance.

Insider Trading Filed: 2026-03-05

The reporting person, Tasos Konidaris, Executive Vice President & CFO, significantly increased his stake in Amneal Pharmaceuticals through the vesting of restricted stock units and performance-based restricted stock units.
Konidaris exercised a total of 630,865 restricted stock units and 458,716 performance-based restricted stock units, resulting in the acquisition of 1,089,581 shares of Amneal's Class A common stock.
The significant insider buying by the CFO suggests a positive outlook on the company's future performance and could signal confidence in the company's growth prospects.

Insider Trading Filed: 2026-03-05

Insider Jason B. Daly, EVP and Chief Legal Officer, has exercised a significant number of restricted stock units and performance-based restricted stock units, acquiring over 300,000 shares of Amneal Pharmaceuticals' Class A common stock.
Daly has also sold a portion of the acquired shares to cover tax withholding obligations, indicating potential liquidity needs or portfolio diversification.
The vesting and subsequent sale of these equity awards suggest that Daly may have confidence in Amneal's future prospects and aligns his interests with shareholders.

Insider Trading Filed: 2026-03-05

Insider Chirag K. Patel, President & Co-CEO, exercised 752,568 stock options and restricted stock units, indicating confidence in the company's future performance.
Patel sold 313,153 shares to cover tax withholding obligations, suggesting he is holding a significant portion of his equity stake in the company.
The vesting of the performance-based restricted stock units, with a 200% payout, suggests the company has achieved strong financial results over the past three years.

Insider Trading Filed: 2026-03-05

Insider Chintu Patel, who serves as Co-CEO, has exercised a significant number of restricted stock units (RSUs) and performance-based RSUs, indicating his confidence in the company's future prospects.
Patel has sold a portion of the shares acquired through the vesting of RSUs and performance-based RSUs to cover tax withholding obligations, suggesting he is not looking to immediately cash out his holdings.
The company has awarded Patel additional RSUs, further aligning his interests with those of shareholders and suggesting the board's continued confidence in his leadership.

Current Report Filed: 2026-01-28

Amneal Pharmaceuticals has reached a nationwide settlement agreement to resolve the majority of opioid-related claims against the company, totaling $88.5 million in cash payments and up to $177.4 million in naloxone nasal spray product over 10 years.
The settlement provides Amneal with a pathway to resolve its significant opioid-related legal liabilities, which could have posed substantial financial and operational risks to the company.
The settlement terms allow for some flexibility, as the settling parties can opt to receive 25% of the naloxone nasal spray value in cash, potentially increasing the total cash payment to $132.9 million.

Current Report Filed: 2026-01-13

Amneal Pharmaceuticals expects to meet or exceed its 2025 financial guidance, indicating continued strong performance.
The company's estimated net leverage has improved from 3.9x as of December 31, 2024 to 3.6x as of December 31, 2025, suggesting improved financial flexibility.
Amneal plans to announce its 2025 full-year guidance at an upcoming investor conference, providing investors with insight into the company's future outlook.

Important Information